Volume 23, Number 2—February 2017
CME ACTIVITY - Dispatch
Risk Factors for Disseminated Coccidioidomycosis, United States
Camila D. Odio1, Beatriz E. Marciano, John N. Galgiani, and Steven M. Holland
Table 1
Summary of disseminated coccidioidomycosis cases reported in the literature*
| Predisposition/no. sites affected |
Sex, no. |
Race/ethnicity, % |
Age, y, median (range) |
Site of disease, % |
Survival, % |
|
| Pregnancy, N = 52 |
Black, 19; white, 14; Hispanic, 11; Asian 3 |
27 (17–38) |
CNS, 18; bone, 5 |
42 |
||
| Immunosuppression,† N = 79 |
M, 59; F, 19 |
Black, 11; white, 37; Hispanic, 20; Asian, 4 |
44 (1–83) |
CNS, 25; bone, 37 |
44 |
|
| Multisite dissemination, N = 100 |
M, 84; F, 16 |
Black, 39; white, 17; Hispanic, 13; Asian, 15 |
36 (1–84) |
CNS, 29; bone, 62 |
72 |
|
| Single site dissemination, N = 139 | M, 115; F, 24 | Black, 32; white, 21; Hispanic, 9; Asian, 17 | 33 (1–73) | CNS, 9; bone, 50 | 99 | |
*CNS, central nervous system.
†Oncologic, n = 8; HIV, n = 12; transplant, n = 24; steroids/immune-modulation, n = 35.
1Current affiliation: Yale–New Haven Hospital, New Haven, Connecticut, USA.
Page created: January 12, 2017
Page updated: January 12, 2017
Page reviewed: January 12, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.